PRECISESADS \u00e9s un projecte de col\u00b7laboraci\u00f3 europeu emmarcat en la Iniciativa sobre Medicaments Innovadors (IMI) participat per 23 centres de recerca i cinc companyies de 12 pa\u00efsos europeus. L\u2019objectiu final \u00e9s trobar tecnologies de diagn\u00f2stic innovadores per relacionar les malalties autoimmunes sist\u00e8miques (SAD) amb canvis en les seves signatures moleculars individuals. <\/p>\n
Els propers 20 i 21 de Febrer tindr\u00e0 lloc a la primera reuni\u00f3 dels participants de PRECISESADS a la seu de la companyia UCB Pharma, a Brussel\u00b7les. <\/p>\n
Les malalties del teixit connectiu (CTD) o malalties autoimmunes sist\u00e8miques (SAD) s\u00f3n un grup de malalties inflamat\u00f2ries cr\u00f2niques amb etiologia autoimmune de diagn\u00f2stic dif\u00edcil i amb poques opcions terap\u00e8utiques. La seva caracter\u00edstica principal \u00e9s la pres\u00e8ncia d\u2019anticossos no espec\u00edfics en el s\u00e8rum de la sang. <\/p>\n
El Lupus eritemat\u00f3s sist\u00e8mic (LES), l\u2019artritis reumatoide (AR) i l\u2019esclerosi sist\u00e8mica (CDC) s\u00f3n les tres malalties m\u00e9s representatives d\u2019aquest grup per\u00f2 existeixen altres s\u00edndromes amb un ampli solapament cl\u00ednic amb aquestes tres. la malaltia mixta del teixit connectiu (EMTC) , la s\u00edndrome de Sj\u00f6gren (SSJ) i la s\u00edndrome d’anticossos antifosfol\u00edpid primari (SAFP) s\u00f3n exemples molt rellevants. Aquestes malalties per separat s\u00f3n poc freq\u00fcents per\u00f2 juntes afecten prop de l\u20191% de la poblaci\u00f3. <\/p>\n
Els metges i els cient\u00edfics que formen part del projecte europeu PRECISESADS estudiaran almenys 2.000 pacients d\u2019aquestes malalties i 600 controls sans, amb l’objectiu d’identificar grups d’individus a trav\u00e9s de la superposici\u00f3 d’aquestes malalties que comparteixen caracter\u00edstiques moleculars i que per tant podrien beneficiar-se de tractaments espec\u00edfics per fer front a aquests elements comuns de la patologia. <\/p>\n
Com a prototip, els investigadors treballaran amb els nous i prometedors tractaments biol\u00f2gics que s’estan desenvolupant per al Lupus eritemat\u00f3s sist\u00e8mic (LES) per\u00f2 que a causa de la classificaci\u00f3 de malalties per separat, no es poden fer servir per tractar les altres malalties de les quals se sospita que tenen una fisiopatologia molecular compartida. <\/p>\n
Segons ha explicat Esteban Ballestar, participant del projecte i cap del grup de cromatina i malaltia de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u201cactualment els pacients tenen poques possibilitats de beneficiar-se de tractaments ja aprovats a causa de l’heterogene\u00eftat dels mecanismes moleculars que resulten de la mateixa classe de malaltia”. “D’altra banda, les companyies farmac\u00e8utiques s’enfronten a enormes problemes quan es tracta d’identificar els punts finals per determinar la utilitat dels f\u00e0rmacs en els assaigs cl\u00ednics i no tenen marcadors biol\u00f2gics que ajudin a avaluar la resposta al tractament\u201d. <\/p>\n
L\u2019objectiu final de PRECISESADS \u00e9s, precisament, aconseguir un mapa molecular de les malalties autoimmunes sist\u00e8miques que funcioni com a guia terap\u00e8utica d\u2019aquest grup de malalties. <\/p>\n
En aquest projecte participen 23 acad\u00e8mics i 5 socis industrials de 12 pa\u00efsos repartits per tot Europa que treballaren durant 5 anys amb un pressupost de 22,7 milions d\u2019euros, dels quals 9,9 provenen del Set\u00e8 Programa Marc de la Comissi\u00f3 Europea per a la Recerca i 9,8 de les companyies farmac\u00e8utiques que hi participen. <\/p>\n
Els resultats de PRECISESADS seran \u00e0mpliament compartits per oferir una nova taxonomia molecular de les malalties autoimmunes sist\u00e8miques (SAD) que ser\u00e0 accessible directament per els metges, pacients, reguladors i desenvolupadors de medicaments per ajudar a definir, refinar i descobrir millors tractaments per les SAD. <\/p>\n
La IMI \u00e9s la Iniciativa sobre Medicaments innovadors, una alian\u00e7a d’empreses entre la Uni\u00f3 Europea i l’associaci\u00f3 de la ind\u00fastria farmac\u00e8utica EFPIA, que existeix per accelerar el desenvolupament de medicaments millors i m\u00e9s segurs.<\/p>\n","protected":false},"excerpt":{"rendered":"
El projecte compta amb m\u00e9s de 22 milions d\u2019euros de finan\u00e7ament per als propers 5 anys Malalties autoimmunes sist\u00e8miques (SAD) PRECISESADS Mapa molecular<\/p>\n","protected":false},"author":6,"featured_media":11045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-11-30 03:55:33","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8424"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8424\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/11045"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}